Article Details

Bluebird gene therapy approved by FDA for rare blood disease | BioPharma Dive

Retrieved on: 2022-08-18 05:58:40

Tags for this article:

Click the tags to see associated articles and topics

Bluebird gene therapy approved by FDA for rare blood disease | BioPharma Dive. View article details on HISWAI: https://www.biopharmadive.com/news/bluebird-bio-fda-approval-beti-cel-beta-thalassemia-zynteglo/629914/

Excerpt

Zynteglo is cleared for transfusion-dependent beta thalassemia, but will come at a cost of $2.8 million per patient. Published Aug.

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up